Who owns BioNTech SE (BNTX)? Elite investor 13F holders
2 tracked elite investors reported holding BioNTech SE as of 2026-06-30, including Dodge & Cox Funds, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Dodge & Cox Funds | BIONTECH SE | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 342199843.00 USD | 3677591.000000 | Shares | add | Original filing |
| D.E. Shaw | BIONTECH SE | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 38841024.00 USD | 417421.000000 | Shares | add | Original filing |
| Tudor Investment | BIONTECH SE | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.